Characterization of joint disease in mucopolysaccharidosis type I mice

International Journal of Experimental Pathology

Volumn 94, Issue 5, 2013, Pages 305-311

  De Oliveira, Patricia G ^a   Baldo, Guilherme ^a,b   Mayer, Fabiana Q ^b   Martinelli, Barbara ^b   Meurer, Luise ^b   Giugliani, Roberto ^a,b   Matte, Ursula ^b   Xavier, Ricardo M ^a,b  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Alpha L iduronidase; Joint disease; Matrix metalloproteinases; Mucopolysaccharidoses type I

Indexed keywords

COLLAGEN; EOSIN; GELATINASE A; GELATINASE B; HEMATOXYLIN; PROTEOGLYCAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHROPATHY; ARTICLE; C57BL 6 MOUSE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMALE; HURLER SYNDROME; IMMUNOHISTOCHEMISTRY; INFLAMMATORY INFILTRATE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; WILD TYPE;

ALPHA-L-IDURONIDASE; JOINT DISEASE; MATRIX METALLOPROTEINASES; MUCOPOLYSACCHARIDOSES TYPE I;

ANIMALS; CARTILAGE; COLLAGEN; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; EXTRACELLULAR MATRIX; FEMALE; IDURONIDASE; JOINT DISEASES; KNEE JOINT; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUCOPOLYSACCHARIDOSIS I; PROTEOGLYCANS; TIME FACTORS;

EID: 84883791221     PISSN: 09599673     EISSN: 13652613     Source Type: Journal    
DOI: 10.1111/iep.12033     Document Type: Article

References (21)

1. Baldo G., Wu S., Howe R.A. et al. (2011a) Pathogenesis of aortic dilatation in mucopolysaccharidosis VII mice may involve complement activation. Mol. Genet. Metab. 104, 608-619.
2. Baldo G., Kretzmann N.A., Tieppo J. et al. (2011b) Bone marrow cells reduce collagen deposition in the rat model of common bile duct ligation. Cell. Sci. Ther. 2, 1-6.
3. Baldo G., Mayer F.Q., Martinelli B. et al. (2012) Evidence of a progressive motor dysfunction in Mucopolysaccharidosis type I mice. Behav. Brain Res. 233, 169-175.
4. Clarke L.A., Russell C.S., Pownall S. et al. (1997) Murine mucopolysaccharidosis type I: targeted disruption of the murine alpha-L-iduronidase gene. Hum. Mol. Genet. 6, 503-511.
5. Giugliani R., Federhen A., Muñoz Rojas M.V. et al. (2010) Enzyme replacement therapy for mucopolysaccharidoses I, II and VI: recommendations from a group of Brazilian F experts. Rev. Assoc. Med. Bras. 56, 271-277 [Article in Portuguese].
6. Hinek A. & Wilson S.E. (2000) Impaired elastogenesis in Hurler disease: dermatan sulfate accumulation linked to deficiency in elastin-binding protein and elastic fiber assembly. Am. J. Pathol. 156, 925-938.
7. Kevorkian L., Young D.A., Darrah C. et al. (2005) Expression profiling of metalloproteinases and inhibitors in cartilage. Int. J. Clin. Exp. Pathol. 86, 131-141.
8. Ma X., Tittiger M., Knutsen R.H. et al. (2008) Upregulation of elastase proteins results in aortic dilatation in mucopolysaccharidosis I mice. Mol. Genet. Metab. 94, 298-304.
9. Martin D.C., Atmuri V., Hemming R.J. et al. (2008) A mouse model of human mucopolysaccharidosis IX exhibits osteoarthritis. Hum. Mol. Genet. 17, 1904-1915.
10. Metcalf J.A., Zhang Y., Hilton M.J., Long F., Ponder K.F. (2009) Mechanism of shortened bones in mucopolysaccharidosis VII. Mol. Genet. Metab. 97, 202-211.
11. Ohmi K., Greenberg D.S., Rajavel K.S., Ryazantsev S., Li H.H., Neufeld E.F. (2003) Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB. Proc. Natl Acad. Sci. USA 100, 1902-1907.
12. Pastores G.M. & Meere P.A. (2005) Musculoskeletal complications associated with lysosomal storage disorders: Gaucher disease and Hurler-Scheie syndrome (mucopolysaccharidosis type I). Curr. Opin. Rheumatol. 17, 70-78.
13. Russell C., Hendson G., Jevon G., et al. (1998) Murine MPS I: insights into the pathogenesis of Hurler syndrome. Clin. Genet. 53, 349-361.
14. Schmitz N., Laverty S., Kraus V.B., Aigner T. (2010) Basic methods in histopathology of joint tissues. Osteoarthr. Cartil. 18(Suppl. 3), s113-s116.
15. Shapiro S.D. (1998) Matrix metalloproteinase degradation of extracellular matrix: biological consequences. Curr. Opin. Cell Biol. 10, 602-608.
16. Simonaro C.M., D'Angelo M., Haskins M.E., Schuchman E.H. (2005) Joint and bone disease in mucopolysaccharidoses VI and VII: identification of new therapeutic targets and biomarkers using animal models. Pediatr. Res. 57(5 Pt 1), 701-707.
17. Simonaro C.M., D'Angelo M., He X. et al. (2008) Mechanism of glycosaminoglycan-mediated bone and joint disease - implications for the mucopolysaccharidoses and other connective tissue diseases. Am. J. Pathol. 172, 112-122.
18. Tylki-Szymanska A., Marucha J., Jurecka A., Syczewska M., Czartoryska B. (2010) Efficacy of recombinant human alpha-L-iduronidase (laronidase) on restricted range of motion of upper extremities in mucopolysaccharidosis type I patients. J. Inherit. Metab. Dis. 33, 151-157.
19. Visigalli I., Delai S., Politi L.S. et al. (2010) Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model. Blood 116, 5130-5139.
20. Wilson S., Hashamiyan S., Clarke L. et al. (2009) Glycosaminoglycan-mediated loss of cathepsin K collagenolytic activity in MPS I contributes to osteoclast and growth plate abnormalities. Am. J. Pathol. 175, 2053-2062.
21. Zhen E.Y., Brittain I.J., Laska D.A. et al. (2008) Characterization of metalloprotease cleavage products of human articular cartilage. Arthritis Rheum. 58, 2420-2431.